Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial.

ABSTRACT:

Background

Clostridioides difficile infection (CDI) is a prevalent, morbid, and expensive disease that recurs in approximately 25% of patients despite treatment. Re-exposure to systemic antibiotics is one of the strongest risk factors for recurrence. Observational evidence and two small randomized controlled trials suggest that secondary vancomycin prophylaxis during antibiotic re-exposure may prevent recurrences, but the current evidence is not definitive.

Methods

SPORES-V is a Bayesian multicenter phase III double-blind randomized controlled trial. Patients with CDI in the preceding 120 days who are re-exposed to systemic antibiotics will be randomized to receive prophylactic oral vancomycin (125 mg orally twice daily while on antibiotics and then once daily for 7 days aft

SUBMITTER: Prosty C 

PROVIDER: S-EPMC13632144 | biostudies-literature | 2026 Jul

REPOSITORIES: biostudies-literature